do not combine glp-1 receptor agonists with dpp-4 inhibitors guideline The effect of DPP GLP 1 Receptor Agonists and
Description
Additionally, some patients with normal weight may risk underweight by privately purchasing GLP-1 RAs off-licence

Rapid weight loss has been associated with gallbladder-related disorders including cholelithiasis and cholecystitis [67, 68], and these adverse events, while rare, have been observed more with GLP-1RAs compared with placebo in clinical trials [21, 38]
ArticlePubMed 4

Firstly, expanding indications is a current hotspot in GLP-1 drug research

Novo Nordisks Wegovy pill (oral semaglutide 25 mg, once daily) has just been approved by the US FDA as the first oral GLP1 receptor agonist for longterm weight management and CV risk reduction in people with overweight or obesity.

Frontiers in Clinical Diabetes and Healthcare
